

## Bromesine hydrochloride vs Standard treatment for COVID-19

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Bromesine hydrochloride compared to Standard treatment be used for COVID-19?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Bromesine hydrochloride	Standard treatment	Relative (95% CI)	Absolute <sup>e</sup> (95% CI)	

### SARS-CoV-2 clearance

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	11/12 (91.7%)	6/6 (100.0%)	<b>RR 0.95</b> (0.72 to 1.27)	<b>50 fewer per 1.000</b> (from 280 fewer to 270 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	---------------	--------------	----------------------------------	---	------------------

### Improvement of lung disease on CT by day 20

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	8/12 (66.7%)	2/6 (33.3%)	<b>RR 2.00</b> (0.60 to 6.64)	<b>333 more per 1.000</b> (from 133 fewer to 1.000 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------	-------------	----------------------------------	---	------------------

### Number of patients discharged by day 20

1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	10/12 (83.3%)	2/6 (33.3%)	<b>RR 2.50</b> (0.78 to 7.97)	<b>500 more per 1.000</b> (from 73 fewer to 1.000 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	---------------	-------------	----------------------------------	--	------------------

### Explanations

a. Downgraded of one level for high risk of performance bias and unclear risk of selection bias

b. Downgraded of two levels for very small sample size

### References

1. Li T, Sun L, Zhang W, et al. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-label Randomized Controlled Pilot Study [published online ahead of print, 2020 Sep 3]. Clin Transl Sci. 2020;10.1111/cts.12881. doi:10.1111/cts.12881